Jacobs Michael R, Anon Jack, Appelbaum Peter C
Department of Pathology, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, OH 44106, USA. mrj6Qcwru.edu
Clin Lab Med. 2004 Jun;24(2):419-53. doi: 10.1016/j.cll.2004.03.011.
Antimicrobial resistance among respiratory tract pathogens represents a significant health care threat. Identifying the antimicrobial agents that remain effective in the presence of resistance, and knowing why, requires a thorough understanding of the mechanisms of action of the various agents as well as the mechanisms of resistance demonstrated among respiratory tract pathogens. The primary goal of antimicrobial therapy is to eradicate the pathogen, via killing or inhibiting bacteria, from the site of infection; the defenses of the body are required for killing any remaining bacteria. Targeting a cellular process or function specific to bacteria and not to the host limits the toxicity to patients. Currently, there are four general cellular targets to which antimicrobials are targeted: cell wall formation and maintenance, protein synthesis, DNA replication, and folic acid metabolism. Resistance mechanisms among respiratory tract pathogens have been demonstrated for all four targets. In general, the mechanisms of resistance used by these pathogens fall into one of three categories: enzymatic inactivation of the antimicrobial, prevention of intracellular accumulation, and modification of the target site to which agents bind to exert an antimicrobial effect. Resistance to some agents can be overcome by modifying the dosage regimens (e.g., using high-dose therapy) or inhibiting the resistance mechanism (e.g., b-lactamase inhibitors), whereas other mechanisms of resistance can only be overcome by using an agent from a different class. Understanding the mechanisms of action of the various agents and the mechanisms of resistance used by respiratory tract pathogens can help clinicians identify the agents that will increase the likelihood of achieving optimal outcomes.
呼吸道病原体中的抗菌药物耐药性对医疗保健构成了重大威胁。要确定在存在耐药性的情况下仍有效的抗菌药物,并了解其原因,就需要深入了解各种药物的作用机制以及呼吸道病原体中表现出的耐药机制。抗菌治疗的主要目标是通过杀死或抑制细菌,从感染部位根除病原体;杀死任何残留细菌需要身体的防御机制。针对细菌特有的而非宿主的细胞过程或功能,可以限制对患者的毒性。目前,抗菌药物有四个一般的细胞靶点:细胞壁的形成和维持、蛋白质合成、DNA复制和叶酸代谢。呼吸道病原体对所有这四个靶点都已表现出耐药机制。一般来说,这些病原体所使用的耐药机制可分为三类:抗菌药物的酶失活、细胞内积累的预防以及药物发挥抗菌作用所结合的靶点的修饰。对某些药物的耐药性可以通过调整给药方案(例如使用高剂量疗法)或抑制耐药机制(例如β-内酰胺酶抑制剂)来克服,而其他耐药机制只能通过使用不同类别的药物来克服。了解各种药物的作用机制以及呼吸道病原体所使用的耐药机制,可以帮助临床医生确定哪些药物更有可能实现最佳治疗效果。